By Josh White
Date: Monday 01 Dec 2025
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Jurriaan Dekkers as its chief financial officer on Monday, strengthening its senior leadership team as the clinical-stage biotech prepared its lead drug candidate, bexmarilimab, for registrational studies.
By Josh White
Date: Monday 20 Oct 2025
(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
By Josh White
Date: Wednesday 27 Aug 2025
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).
| Currency | UK Pounds |
| Share Price | 182.50p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 262.50p |
| 52 Week Low | 150.00p |
| Volume | 264 |
| Shares Issued | 114.42m |
| Market Cap | £208.82m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 1 |
| Buy | 3 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 5 |

| No dividends found |
| Time | Volume / Share Price |
| 13:18 | 259 @ 183.00p |
| 12:09 | 3 @ 190.00p |
| 12:09 | 2 @ 190.00p |
| CEO | Juho Jalkanen |
| Chair | Tuomo Pätsi |
| CFO | Jurriaan Dekkers |
You are here: research